<DOC>
	<DOCNO>NCT00853372</DOCNO>
	<brief_summary>This phase 2 study open-label , multi-center study determine safety tolerability AMG 386 combination sunitinib treatment subject metastatic renal cell carcinoma .</brief_summary>
	<brief_title>AMG 386 Phase 2 Open-Label Renal Cell Carcinoma ( RCC ) Study 1st Line After Cytokine Failure Combination With Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Subjects must histologically confirm metastatic RCC clear cell component Low intermediate risk accord Memorial Sloan Kettering Cancer Center ( MSKCC ) prognostic risk classification Measurable disease least one unidimensionally measurable lesion per RECIST guideline modification Adequate organ hematological function evidence laboratory study conduct Screening ECOG 0 1 Disease relate Known history central nervous system metastasis . Previous treatment ( exclude surgery , prior cytokinebased immunotherapy palliative radiotherapy ) advance metastatic renal cell carcinoma Focal radiation therapy palliation pain bony metastasis within 14 day enrollment . Medications Currently previously treat sunitinib small molecule inhibitor VEGF Currently previously treat agent neutralize VEGF Currently previously treat AMG 386 , molecule inhibit angiopoietins Tie2 receptor Currently previously treat agent inhibit mammalian target rapamycin ( mTOR ) Current within 30 day prior enrollment treatment immune modulators Concomitant previous use within 30 day prior enrollment strong inducer CYP3A4 Concomitant previous use amiodarone within 6 month prior enrollment General medical Clinically significant cardiovascular disease within 12 month prior enrollment , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , cerebrovascular accident , transient ischemic attack , congestive heart failure , arrhythmia control outpatient medication , percutaneous transluminal coronary angioplasty/stent Major surgery within 28 day prior enrollment still recover prior surgery Uncontrolled hypertension define diastolic &gt; 90 mmHg OR systolic &gt; 150 mmHg . The use antihypertensive medication control hypertension permit . Other Other investigational procedure exclude Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) , subject receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>